[Carboplatin treatment by continuous infusion in combination for relapsed and refractory acute myeloid leukemia]. 1994

T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
First Dept. of Internal Medicine, Fukui Medical School.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016190 Carboplatin An organoplatinum compound that possesses antineoplastic activity. cis-Diammine(cyclobutanedicarboxylato)platinum II,Blastocarb,CBDCA,Carboplat,Carbosin,Carbotec,Ercar,JM-8,NSC-241240,Nealorin,Neocarbo,Paraplatin,Paraplatine,Platinwas,Ribocarbo,JM 8,JM8,NSC 241240,NSC241240

Related Publications

T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
October 1995, American journal of clinical oncology,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
July 1995, Leukemia,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
June 2021, HemaSphere,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
March 2017, Current treatment options in oncology,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
April 2009, Leukemia research,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
April 2021, Zhongguo shi yan xue ye xue za zhi,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
January 2017, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
August 1992, Leukemia,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
January 1993, Cancer chemotherapy and pharmacology,
T Yamauchi, and H Tsutani, and S Nakayama, and S Imamura, and K Inai, and S Wataya, and T Tanaka, and A Yoshida, and H Iwasaki, and T Fukushima
January 1989, Bone marrow transplantation,
Copied contents to your clipboard!